Muscle Pharm Corp. announced unaudited earnings results for the first quarter ended March 31, 2012. The company reported an increase in its unaudited sales and a reduction in its unaudited operating loss for the first quarter ended March 31, 2012 as compared to March 31, 2011. Net sales for the three months ending March 31, 2012 increased more than five fold to approximately $16.6 million from approximately $3.0 million for 2011 first quarter. Loss from operations narrowed to approximately $727,000 during the first quarter of 2012, from $1.1 million for the 2011 first quarter. Net loss was approximately $16.0 million, which included derivative expense of approximately $1.5 million, change in fair value of derivative liabilities of approximately $8.4 million, loss on settlement of accounts payable and debt of approximately $2.9 million and interest expense of approximately $2.6 million. This compares to net loss for the 2011 first quarter of approximately $5.0 million, which included derivative expense of approximately $1.4 million, change in fair value of derivative liabilities of $132,000, loss on settlement of accounts payable and debt of $1.9 million and interest expense of $519,000. The company remains on track to achieve net sales of $75 million for the full 2012 year, even with the change in presentation of net sales and advertising. The company believes it can generate $4 million of EBITDA in the final two quarters of 2012.